<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107714">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083263</url>
  </required_header>
  <id_info>
    <org_study_id>CF2012-1</org_study_id>
    <nct_id>NCT02083263</nct_id>
  </id_info>
  <brief_title>Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis</brief_title>
  <official_title>Study of Non Invasive Ventilation With High Pressure as Airways Clearance Technique in Adults Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the use of Non invasive ventilation the patients with cystic fibrosis will have better
      lung function (FEV1).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3 months intervention between PEP an Bilevel. The patients will follow up under 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Lung function: FEV1% of predictive value, FVC% of predictive value, Lung clearance index.</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>FEV1% of predictive value, FVC% of predictive value, Lung clearance index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood gases:1 month after chest physiotherapy will take blood gases (kpa).</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>1 month after chest physiotherapy will take blood gases (kpa).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Bilevel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilevel, 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEP mask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEP mask, 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilevel</intervention_name>
    <description>3 months</description>
    <arm_group_label>Bilevel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PEP mask</intervention_name>
    <description>3 months</description>
    <arm_group_label>PEP mask</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CF older than 18 years

          -  FEV1 between 20% and 69% of predictive.

          -  No acute exacerbation.

          -  No Burkhordelia Cepacia/MRSA colonization.

        Exclusion Criteria:

          -  Children under 18 year

          -  acute exacerbation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecilia Rodriguez, Physio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cecilia Rodriguez</name>
      <address>
        <city>Stockholm</city>
        <zip>14178</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Cecilia Rodriguez</investigator_full_name>
    <investigator_title>Specialist Physiotherapist</investigator_title>
  </responsible_party>
  <keyword>Lung function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
